Form Type: 4

SEC EDGAR Link
Accession Number:0000899243-16-021091
Date:2016-05-26
Issuer: EMERGENT BIOSOLUTIONS INC. (EBS)
Original Submission Date:

Reporting Person:

EL-HIBRI FUAD
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG, MD 20879

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2016-05-26 M 24,594 a $15.91 1,698,667 direct
COMMON STOCK 2016-05-26 S 24,594 d $42.90 1,674,073 direct
COMMON STOCK 2016-05-26 S 15,165 d $43.50 1,658,908 direct
COMMON STOCK 2016-05-26 0 $0.00 2,350,331 indirect
COMMON STOCK 2016-05-26 0 $0.00 1,524,155 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
EMPLOYEE STOCK OPTION (RIGHT TO BUY) 15.91 2016-05-26 deemed execution date M 24,594 (d) 2017-03-08 common stock 24,594 $15.91 0 direct
Footnotes
IDfootnote
f1 the transactions reported herein were effectuated by the reporting person pursuant to two separate trading plans adopted on february 29, 2016, each of which are intended to comply with rule 10b5-1(c) under the exchange act.
f2 the selling price of $42.90 is reflective of the weighted average sale price of all transactions reported on this line. the prices for the transactions reported on this line range from $42.90 to $42.91, inclusive. the reporting person undertakes to provide, upon request by the staff of the securities and exchange commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
f3 mr. el-hibri's holdings through intervac, l.l.c. include 1,638,403 shares of common stock held by mr. el-hibri and his wife, as tenants by the entirety, through their 37.7% equity interest in intervac, l.l.c.; 127,721 shares held by mr. el-hibri's wife; and 584,207 shares held by trusts indirectly controlled by mr. el-hibri or his wife. mr. el-hibri disclaims beneficial ownership, for purposes of section 16 of the exchange act or otherwise, of those shares held solely by his wife and those shares held by the trusts.
f4 mr. el-hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in biovac, l.l.c. biovac, l.l.c. is the direct owner of 1,524,155 shares of common stock. mr. el-hibri disclaims beneficial ownership of the shares of common stock directly owned by biovac, l.l.c. for purposes of section 16, except to the extent of his pecuniary interest in 1,359,546 shares.
f5 the options vested in three equal installments on march 9, 2011, march 9, 2012 and march 9, 2013.
WhaleWisdom Logo

Elevate your investments